Last updated: October 23, 2026
EXTINA is a prescription ketoconazole 2% topical foam approved for seborrheic dermatitis. Its commercial trajectory has followed the standard dermatology lifecycle: premium branded launch, limited differentiation from lower-cost ketoconazole products, loss of regulatory exclusivity, and increasing generic substitution. Public filings do not separately disclose EXTINA revenue, so the product’s financial performance must be assessed through prescription demand, competitive pricing, FDA approvals, reimbursement, and brand-portfolio ownership rather than reported product sales.
What is EXTINA and what is it used for?
EXTINA contains ketoconazole 2% in a topical foam formulation. The FDA-approved indication is topical treatment of seborrheic dermatitis in immunocompetent patients aged 12 years and older.[1]
| Product attribute |
EXTINA data |
| Active ingredient |
Ketoconazole |
| Strength |
2% |
| Dosage form |
Topical foam |
| FDA indication |
Seborrheic dermatitis |
| Administration |
Applied once daily for four weeks |
| Original regulatory application |
NDA 21-659 |
| Therapeutic class |
Topical antifungal |
| Primary competitors |
Ketoconazole cream, shampoo, foam and other seborrheic-dermatitis therapies |
| FDA pathway |
New drug application, followed by generic ANDA competition |
EXTINA’s commercial distinction is the foam vehicle. Ketoconazole itself is an established antifungal with long-standing generic competition in creams and shampoos. The foam was intended to improve application to hair-bearing or inflamed scalp areas and to provide a differentiated dermatology formulation.
When did EXTINA lose exclusivity?
EXTINA’s meaningful commercial exclusivity has expired. The product no longer has the exclusivity profile associated with a newly launched branded dermatology product.
The original NDA approval created an initial period of FDA regulatory exclusivity, while formulation and manufacturing patents provided additional protection. Those protections did not create a durable monopoly because ketoconazole was already widely available in other dosage forms and generic manufacturers could compete through ANDA filings once relevant barriers expired.
The key commercial events were:
| Period |
Commercial event |
Market effect |
| 2000s |
FDA approval of ketoconazole foam under NDA 21-659 |
Created a branded foam segment |
| Initial launch period |
Brand-led promotion and dermatology distribution |
Supported premium pricing |
| Later lifecycle |
Expansion of generic ketoconazole products in other formulations |
Reduced product differentiation |
| Post-patent period |
Generic foam competition and payer pressure |
Increased substitution and price erosion |
| Current market |
Mature topical antifungal category |
Limited growth and lower brand leverage |
The precise date on which each patent right expired depends on the patent, patent-term adjustment, patent-term extension, and applicable Orange Book listing. The FDA Orange Book, rather than commercial databases, is the controlling source for current listed patents and exclusivity status.[2]
What patents protect EXTINA?
EXTINA’s protection was based primarily on formulation and foam-delivery technology rather than a new chemical entity. Ketoconazole itself is an old active ingredient and does not provide meaningful composition-of-matter protection for the product.
Formulation and foam patents
Topical foams can be protected through claims covering:
- The composition of the foam base
- Solvent and propellant systems
- Ketoconazole concentration
- Foam stability
- Delivery to skin or scalp
- Manufacturing processes
- Use in seborrheic dermatitis
The commercial value of these patents was narrower than that of a chemical patent. A competitor could potentially avoid infringement by using a different vehicle, a different propellant system, a different manufacturing process, or another dosage form.
The FDA Orange Book identifies patents submitted by NDA sponsors for approved products. Patent listings may include formulation, method-of-use or drug-product claims. Orange Book listing does not establish that every listed claim would survive invalidity or noninfringement challenges.[2]
How strong is the EXTINA patent estate?
The EXTINA patent estate is commercially moderate to weak after loss of exclusivity.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
Weak; ketoconazole is an established generic active |
| New chemical entity protection |
None of practical relevance |
| Foam formulation protection |
Historically important |
| Method-of-use protection |
Narrow, because seborrheic dermatitis is a conventional antifungal indication |
| Manufacturing protection |
Potentially relevant but usually avoidable through process changes |
| Barrier to generic cream or shampoo |
Low |
| Barrier to generic foam |
Historically higher, but reduced after patent expiry |
| Long-term exclusivity value |
Limited |
The strongest commercial barrier was the combination of a proprietary foam formulation, FDA approval and physician familiarity. That barrier was more meaningful before generic foam entrants became available.
What is the Orange Book status of EXTINA?
EXTINA is listed in FDA drug databases under NDA 21-659. The Orange Book provides the authoritative record for approved products, therapeutic-equivalence ratings, patent submissions and exclusivity information.[2]
For commercial analysis, the relevant distinction is between:
- The original branded NDA product.
- Authorized generic or generic ketoconazole foam products.
- Generic ketoconazole products in creams, shampoos and other dosage forms.
The existence of generic ketoconazole in another dosage form does not automatically establish therapeutic equivalence to EXTINA foam. FDA therapeutic-equivalence determinations are product-specific and depend on the approved dosage form, formulation and regulatory application.[2]
Which companies are challenging or competing with EXTINA?
The main competitive threat is generic substitution rather than a direct branded challenger. Generic manufacturers can compete through ANDA approvals covering ketoconazole foam or through lower-cost alternative dosage forms.
The competitive field includes:
- Generic ketoconazole cream manufacturers
- Generic ketoconazole shampoo manufacturers
- Generic ketoconazole foam manufacturers
- Branded topical corticosteroids
- Topical calcineurin inhibitors
- Other antifungal products
- Over-the-counter anti-dandruff and seborrheic-dermatitis products
The most important competitors do not need to replicate every commercial attribute of EXTINA. Payers often treat treatment of seborrheic dermatitis as a lower-cost topical category. A patient may receive ketoconazole shampoo, cream or another medicated product rather than foam depending on body site, coverage and prescriber preference.
What generic entry risks exist for EXTINA?
Generic entry risk is high because the active ingredient is well established, the indication is common and alternative ketoconazole dosage forms are widely available.
Generic launch scenarios
| Scenario |
Likely commercial consequence |
| One generic foam entrant |
Moderate price erosion and increased pharmacy substitution |
| Multiple generic foam entrants |
Rapid net-price compression |
| Continued preference for foam |
Brand retains some prescriber and patient demand |
| Payer preference for cream or shampoo |
Substantial volume migration away from EXTINA |
| Limited generic availability |
Brand may retain niche pricing in selected plans |
| Authorized generic launch |
Faster reduction in branded net sales |
The product’s remaining commercial value depends more on formulary positioning, patient preference and physician habits than on patent exclusivity.
A generic manufacturer may also face technical barriers. Foam products require control of viscosity, spreadability, propellant behavior, microbial quality, container compatibility and dose delivery. These barriers can delay entry relative to a conventional cream. They do not generally support long-term premium pricing once several manufacturers obtain approval.
How does EXTINA compare with other ketoconazole products?
| Product type |
Main use pattern |
Commercial position versus EXTINA |
| Ketoconazole 2% cream |
Localized cutaneous fungal or seborrheic conditions |
Lower-cost, established generic alternative |
| Ketoconazole 2% shampoo |
Scalp seborrheic dermatitis and dandruff |
Strong practical substitute |
| Ketoconazole 2% foam |
Seborrheic dermatitis, including hair-bearing areas |
More differentiated delivery system |
| OTC anti-dandruff products |
Mild or maintenance treatment |
Price-sensitive alternative |
| Topical corticosteroids |
Inflammatory symptom control |
Different pharmacologic class and risk profile |
| Nonsteroidal anti-inflammatory topicals |
Selected inflammatory dermatology uses |
Competitive in treatment strategy, not direct equivalence |
EXTINA’s advantage is convenience and vehicle preference. Its disadvantage is that ketoconazole is not commercially unique and many patients can be treated with cheaper products.
What is the FDA regulatory status of EXTINA?
EXTINA was approved through the FDA’s NDA pathway for seborrheic dermatitis. The FDA label specifies topical use and a four-week treatment course.[1]
The product’s regulatory value is narrower than that of a systemic medicine because:
- The active ingredient has extensive prior use.
- Safety and efficacy expectations are established for topical ketoconazole.
- The indication is common and generally managed in primary care or dermatology.
- Generic manufacturers can use the ANDA pathway if they demonstrate pharmaceutical equivalence and bioequivalence or meet applicable product-specific requirements.
The FDA’s approval of generic products can reduce brand utilization even when EXTINA remains approved and commercially available.
What patent litigation and Paragraph IV challenges affect EXTINA?
The principal litigation risk for a product such as EXTINA arises from ANDA filings containing Paragraph IV certifications. Under the Hatch-Waxman framework, a generic applicant may assert that listed patents are invalid, unenforceable or not infringed. The NDA holder can sue within the statutory period, potentially triggering a 30-month stay of final approval for the challenged ANDA.[3]
The commercial significance of Paragraph IV litigation depends on:
- The number of listed patents
- The remaining patent term
- Whether the patents cover the foam itself or only narrow uses
- The likelihood of an at-risk launch
- The strength of design-around options
- The economics of settlement
For an older topical product, litigation value usually declines as patent terms near expiration. A settlement may involve a licensed entry date, an authorized generic arrangement, or no restriction beyond the patent outcome. No current settlement should be treated as commercially material without confirmation in court records, FDA listings or SEC filings.
What licensing deals and ownership changes affect EXTINA?
EXTINA was originally associated with the dermatology companies that developed and commercialized the foam formulation. Ownership and labeling arrangements may change through dermatology portfolio transactions, licensing agreements or transfers of marketing rights.
The product’s financial analysis should separate:
- NDA ownership
- Trademark ownership
- Commercial marketing rights
- Manufacturing rights
- Authorized-generic rights
- Distribution arrangements
These rights are not necessarily held by the same company. Public company filings may report dermatology portfolios in aggregate rather than disclose EXTINA revenue separately. As a result, a transaction involving a dermatology portfolio does not establish the standalone value of EXTINA without product-level sales data.
What is EXTINA’s financial trajectory?
Publicly available financial disclosures do not provide a reliable standalone revenue series for EXTINA. The likely trajectory is:
- Initial revenue growth after launch, supported by differentiated foam delivery and branded dermatology promotion.
- Mature-brand stabilization as prescribing habits formed.
- Gradual pressure from ketoconazole cream and shampoo alternatives.
- Accelerated decline after generic foam entry and loss of formulation exclusivity.
- Residual niche sales where patients or prescribers prefer foam and reimbursement remains favorable.
Revenue exposure is likely modest relative to major pharmaceutical brands because seborrheic dermatitis is treated with inexpensive topical products and the active ingredient is generic. The product may still generate cash flow through an established prescription base, but its strategic value is more likely to lie in portfolio breadth, dermatology channel access and manufacturing infrastructure than in high-growth revenue.
Key financial drivers
| Driver |
Directional impact |
| Generic foam approvals |
Negative for price and volume |
| Generic cream and shampoo availability |
Negative for volume |
| Brand formulary exclusion |
Negative |
| Foam preference among dermatologists |
Positive |
| Refill and maintenance use |
Positive |
| Patient copay differentials |
Strongly negative when brand copay rises |
| Dermatology sales-force support |
Positive but difficult to justify after generic entry |
| Manufacturing complexity |
Can slow competitors but raises cost |
| OTC substitution |
Negative for prescription demand |
What geographic coverage does EXTINA have?
EXTINA’s strongest commercial relevance is in the United States, where its FDA approval, Orange Book listing and prescription reimbursement determine market access. International availability depends on country-specific registrations, trademarks, local licensees and commercial decisions.
A U.S. patent or FDA approval does not establish protection or marketing rights in Europe, Canada, Japan or other jurisdictions. Geographic analysis requires separate review of:
- National product registrations
- Local patent registers
- Supplementary protection certificates where applicable
- Trademark ownership
- Local generic approvals
- Reimbursement decisions
- Import and manufacturing arrangements
Key Takeaways
- EXTINA is ketoconazole 2% foam for seborrheic dermatitis.
- Its commercial differentiation is the foam delivery system, not the active ingredient.
- Regulatory and patent exclusivity have expired or ceased to provide a material long-term barrier.
- Generic competition is the primary risk to volume and net price.
- Ketoconazole cream and shampoo are important substitutes even when they are not therapeutically equivalent to the foam.
- Public disclosures do not provide a dependable standalone EXTINA revenue history.
- The product is a mature dermatology asset with residual niche value rather than a high-growth pharmaceutical brand.
- The most important current diligence points are FDA generic approvals, Orange Book listings, formulary status, labeler ownership and any active Paragraph IV litigation.
Frequently Asked Questions
Is EXTINA still available by prescription?
EXTINA is an FDA-approved prescription product, but commercial availability and pharmacy stocking can vary by manufacturer, distributor and payer coverage.
Is generic ketoconazole foam equivalent to EXTINA?
A generic product may be therapeutically equivalent only if FDA has assigned the relevant equivalence rating for that specific product. Ketoconazole cream or shampoo should not be assumed to be equivalent to ketoconazole foam.
Does EXTINA have composition-of-matter patent protection?
No meaningful composition-of-matter protection remains for ketoconazole. Historical protection centered on the foam formulation, delivery system and related methods.
Can a generic launch EXTINA before every patent expires?
A generic applicant may launch after patent expiry, after a successful Paragraph IV challenge, under a settlement license, or at risk if it accepts potential infringement liability. The legal outcome depends on the specific listed patents and litigation record.
Is EXTINA a material revenue contributor for its current commercial owner?
Standalone revenue is not publicly reported with sufficient consistency to support that conclusion. Based on the mature category, generic competition and low-cost alternatives, EXTINA is more likely to be a niche or portfolio product than a major revenue driver.
References
-
U.S. Food and Drug Administration. (n.d.). EXTINA (ketoconazole) foam, 2% prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-instructions
